A Pioneer in Diagnostic Imaging
Bayer HealthCare Pharmaceuticals is a worldwide leading specialty pharmaceutical company. Its research and business activities are focused on the following areas: Diagnostic Imaging, General Medicine, Specialty Medicine and Women's Healthcare. With innovative products, Bayer HealthCare Pharmaceuticals aims for leading positions in specialized markets worldwide. Using new ideas, Bayer HealthCare Pharmaceuticals aims to make a contribution to medical progress and strives to improve the quality of life. We at Bayer HealthCare Pharmaceuticals combine our expertise in diagnostics and therapeutics to offer comprehensive services from early diagnosis to life-prolonging therapies.
Enabling a precise diagnosis
The ability to identify a disease at an early stage and with high precision is a primary component of successful disease management, resulting in a better quality of life for the patient. Within the broad range of diagnostic methods available, in-vivo imaging procedures are especially important because they make tissue and organs visible in their natural positions within the human body. Contrast media enhance the quality of images of structures and functions.
The diagnostic imaging business of Bayer HealthCare Pharmaceuticals is a world leader in developing and manufacturing contrast media for use in X-ray, computed tomography (CT) and magnetic resonance imaging (MRI). Of all the companies supplying contrast media, Bayer HealthCare Pharmaceuticals is the one with the strongest in-house therapeutic expertise. We use our knowledge to deliver diagnostic imaging products and services that are very much clinically oriented with the emphasis on a safe, fast, precise diagnosis every time. Our aspiration is that patients experience the least invasive and the most efficient imaging procedure, and that our customers have confidence in the usefulness of the diagnostic information acquired with our in-vivo imaging products. We offer healthcare professionals complete support, whether they work in radiology, cardiology, oncology, neurology or other therapeutic specialties.
The Diagnostic Imaging business unit collaborates with Bayer’s subsidiary MEDRAD, the market leader in contrast media injectors and a supplier of other state-of-the-art technical accessories. Our goal is to improve available diagnostic in-vivo imaging methods and to develop new, innovative tools for an earlier, more sensitive and specific diagnosis.
Pioneering diagnostic imaging
As a leading company in the contrast media market, Bayer Pharma AG has always been a pioneer in the field of diagnostic imaging. Milestones in our company history include the introduction of one of the first X-ray contrast media in 1930 and the world’s first contrast medium for magnetic resonance imaging in 1988. At the beginning of the new century we began introducing innovative organ-specific contrast media for MRI and launched the first of a new class of blood-pool contrast agents for use in magnetic resonance angiography.
